Spondyloarthritis

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

Early, Sustained Improvements With Apremilast in Biologic-Naive Psoriatic Arthritis

By

In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

Glucocorticoid Cumulative Dose Has No Effect on BMD, Fracture Risk in Psoriasis, PsA

By

The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

By

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

Effects of Maternal axSpA Disease Activity on Pregnancy Outcomes Examined

By

A systematic review revealed no signal for increased pregnancy loss in patients with axial spondyloarthritis.

Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis

Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis

By

Tofacitinib may provide a fast and prolonged analgesic effect in patients with rheumatoid arthritis or psoriatic arthritis who are unresponsive to csDMARD or to TNFi, as well as in individuals with ankylosing spondylitis.

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

Ustekinumab, TNF Inhibitors Improve 6-Month Outcomes in Psoriatic Arthritis

By

Researchers sought to evaluate the efficacy, tolerability, and persistence of TNFi and ustekinumab in patients with psoriatic arthritis initiating first-line, second-line, or third-line biologic DMARDs.

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis

By

Investigators assessed the 12-week efficacy and safety of bimekizumab in patients with active ankylosing spondylitis.

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

By

Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.

Reduced Structural Damage in Early Axial Spondyloarthritis Linked to Increased IL-31 Levels

Reduced Structural Damage in Early Axial Spondyloarthritis Linked to Increased IL-31 Levels

By

Increased interleukin-31 levels may protect against structural damage in patients with axial spondyloarthritis.

Extended Disease Duration Increases Risk for IBD, Uveitis in Axial Spondyloarthritis

Extended Disease Duration Increases Risk for IBD, Uveitis in Axial Spondyloarthritis

By

Axial spondyloarthritis disease duration was associated with higher risk of developing acute anterior uveitis and inflammatory bowel disease, but not psoriasis.

High Rate of Hidradenitis Suppurativa Observed in Patients With Axial Spondyloarthritis

High Rate of Hidradenitis Suppurativa Observed in Patients With Axial Spondyloarthritis

By

Hidradenitis suppurativa is more common in patients with axial spondyloarthritis compared with the general population.

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

By

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

Baseline Characteristics Associated With Response to Biologic Therapy in PsA

By

Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

By

A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

Alternative Measurement of Psoriasis Severity Effective in CZP-Treated Psoriatic Arthritis

By

The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.

Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial Spondyloarthritis

Certolizumab Pegol Demonstrates Positive Results in Phase 3 Trial for Nonradiographic Axial Spondyloarthritis

By

Results from a phase 3 trial show that certolizumab pegol improves the signs and symptoms of nonradiographic axial spondyloarthritis compared with placebo at 52 weeks.

Illness Perceptions Mediate Back Pain, Quality of Life in Early Axial Spondyloarthritis

Illness Perceptions Mediate Back Pain, Quality of Life in Early Axial Spondyloarthritis

By

Illness perceptions are important in the relationship between back pain and health-related quality of life in patients suspected of axial spondyloarthritis.

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

CONTEST Not Superior to PEST Questionnaire for Diagnosing Psoriatic Arthritis

By

The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.

Myocardial Infarction Risk in Osteoarthritis, Spondyloarthritis Linked to Certain NSAIDs

Myocardial Infarction Risk in Osteoarthritis, Spondyloarthritis Linked to Certain NSAIDs

By

The risk for myocardial infarction in patients with spondyloarthritis is increased in patients taking diclofenac, but not in patients taking naproxen.

Prevalence, Risk Factors of Renal Impairment Evaluated in Spondyloarthritis

Prevalence, Risk Factors of Renal Impairment Evaluated in Spondyloarthritis

By

Investigators sought to evaluate the prevalence of renal dysfunction in patients with SpA using data from the ASAS-COMOSPA study.

Hitting the Target in Psoriatic Arthritis: Which Outcome Measures Are Best?

Hitting the Target in Psoriatic Arthritis: Which Outcome Measures Are Best?

By

Experts are still debating the utility of a unidimensional composite score compared with a multidimensional score for the assessment of disease activity in psoriatic arthritis.

Power Doppler Ultrasound Abnormalities Evaluated in Psoriatic Arthritis

Power Doppler Ultrasound Abnormalities Evaluated in Psoriatic Arthritis

By

Researchers sought to evaluate the prevalence rates of peripheral joint, enthesis, tendon, and bursa abnormalities by power Doppler ultrasound in patients with psoriatic arthritis and patients with psoriasis without clinical signs of arthritis.

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

By

Researchers aimed to compare the disease burden of patients with psoriatic arthritis with low disease activity according to 2 definitions.

Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis

Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis

By

Results confirm that juvenile spondyloarthritis is characterized by its peripheral pattern at disease onset, with peripheral arthritis and enthesitis.

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

By

Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

By

Researchers sought to investigate the utility of adding structural MRI lesions of the sacroiliac joints to the imaging criterion of the ASAS axSpA criteria.

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

By

Results from the ABILITY-1 study show sustained clinical and functional improvements with adalimumab treatment in nonradiographic axial spondyloarthritis.

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

By

The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

By

Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

By

Researchers found that disease activity was highest during the second trimester of pregnancy.

Sign Up for Free e-newsletters